Stock Ratings / Health Care / CSTL / financials

LMRI (58) TRUP (64) FRNM (31) ALHC (67) ⌘ Pro Terminal →

Castle Biosciences Inc. (CSTL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$38.51 +4.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Castle Biosciences Inc. (CSTL) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CSTL)Realized 20D OHLCV Swing Band: ±11.2%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CSTL Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$28.3M (8.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $219.8M

FY24

Rev $332.1M

FY25

Rev $344.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$344.2M	79.4%	-12.4%	-$24.2M	$28.3M	-9.3%
FY 2024	$332.1M	81.9%	2.6%	$18.2M	$36.5M	2%
FY 2023	$219.8M	79.4%	-30.9%	-$57.5M	-$5.6M	-9.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CSTL)

✓Walkthrough of CSTL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CSTL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.25%⚡ TESTING RESISTANCE

2026-10-30O $38.03H $38.51L $36.73C $38.51VOL 334.3K

RES: $39.72SUP: $32.29SMA50: $34.22SMA200: $28.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CSTL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CSTL Butterfly Map → + Track CSTL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CSTL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CSTL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CSTL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CSTL)

Health Care Rank #203 of 1016 ⚔️ LMRI vs CSTL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CSTL vs. LMRI, TRUP, FRNM, ALHC)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Castle Biosciences Inc. (CSTL) ranks #203 by composite RQD confidence (60/100, grade C-) and #339 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. ALHC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with CSTL at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CSTL ACTIVE Castle Biosciences Inc.	C-	60/100	—	79.4%	-9.3%	+4.99%	$1.18B	Benchmark Subject
LMRI Lumexa Imaging Holdings Inc.	D+	58/100	—	—	—	+0.95%	$1.13B	/lmri-vs-cstl →
TRUP Trupanion Inc.	C	64/100	68.2x	16.1%	3.1%	+2.27%	$1.32B	/trup-vs-cstl →
FRNM Freenome Inc.	E	31/100	—	—	-3.4%	-4.32%	$1.38B	/frnm-vs-cstl →
ALHC Alignment Healthcare Inc.	C+	67/100	—	—	13.9%	-1.47%	$1.67B	/alhc-vs-cstl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001447362

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Castle Biosciences Inc. (CSTL) reported GAAP revenue of $344.2M (+3.7% vs. FY2024 revenue of $332.1M , and +56.6% cumulative change since FY2023) , GAAP net income of -$24.2M, operating cash flow of $64.3M, and free cash flow of $28.3M (-22.5% YoY). On the balance sheet, CSTL closed FY2025 with $578.6M in total assets against $9.6M in total debt (Altman Z-Score: 6.97, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$344.2M	-$24.2M	$64.3M	$28.3M	$578.6M	$9.6M
FY2024 (FY)	2024-12-31	$332.1M	$18.2M	$64.9M	$36.5M	$531.2M	$9.7M
FY2023 (FY)	2023-12-31	$219.8M	-$57.5M	-$5.6M	-$5.6M	—	—

3. CSTL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CSTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Castle Biosciences Inc. (NASDAQ: CSTL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $38.51 (+4.99% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CSTL ranks #203 in composite RQD confidence.

How does CSTL compare to LMRI and TRUP in the Health Care sector?

Within the Health Care sector (Medical Specialities), CSTL carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of -9.3%. By comparison, LMRI (Lumexa Imaging Holdings Inc.) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.13B) and TRUP (Trupanion Inc.) posts a C grade (64/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CSTL?

Per CSTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447362), Castle Biosciences Inc. generated $344.2M in revenue (+3.7% YoY), -$24.2M in net income, and $28.3M in free cash flow against $578.6M in total assets and $9.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CSTL trading relative to its 50-day, 200-day, and 52-week technical levels?

CSTL last traded at $38.51 (+4.99% on volume of 723,935 shares), positioning the stock +12.54% above its 50-day simple moving average ($34.22) and +34.98% above its 200-day simple moving average ($28.53). Across its 52-week range of $17.72 to $44.28, CSTL sits at the 78.3% percentile with a 14-day RSI of 60.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.2% ($34.20 to $42.82).